To learn more, please call our Research Department at (513) 751-2273 or email
mhoelle@ohcare.com
|
Adjuvant
|
|
Study number:
|
BRE 177 Amgen, Inc 20060359
|
|
Protocol title:
|
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast CAncer at High Risk of Recurrence (D-CARE)
|
|
Status
|
Open
|
|
Adjuvant, her2+
|
|
Study number:
|
BRE-193 Genetech BO25126/APHINITY
|
|
Protocol title:
|
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy plus Trastuzumab plus Placebo versus Chemotherapy plus Trastuzumab plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2-positive Primary Breast Cancer
|
|
Status
|
Open
|
|
neoadjuvant
|
|
Study number:
|
BRE 186 SCRI
|
|
Protocol title:
|
Phase 2 Trial or Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
|
|
Status
|
Open
|
|
metastatic, first-line, her2-
|
|
Study number:
|
BRE 138 SCRI
|
|
Protocol title:
|
Phase I/II Trial of Sorafenib Plus Ixabepilone as First-Line Treatment for Patients with HER2-Negative Metastatic Breast Cancer
|
|
Status
|
Open
|
|
metastatic, refractory, her2+
|
|
Study number:
|
BRE 185 Eli Lilly I1Y-MC-JFBE
|
|
Protocol title:
|
A Randomized Phase 2 Study of LY2523355 versus Ixabepilone in Patients with Metastatic Breast Cancer Who Have Received Prior Taxane Therapy
|
|
Status
|
Open
|
|
metastatic, refractory, her2-
|
|
Study number:
|
BRE 183 Imclone Systems IMCL CP20-0903
|
|
Protocol title:
|
An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC 1121B) Drug Product or IMC 18F1 in Combination with Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally-advanced or Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane Therapy
|
|
Status
|
Open
|
|
Study number:
|
BRE 185 Eli Lilly I1Y-MC-JFBE
|
|
Protocol title:
|
A Randomized Phase 2 Study of LY2523355 versus Ixabepilone in Patients with Metastatic Breast Cancer Who Have Received Prior Taxane Therapy
|
|
Status
|
Open
|
|
metastatic, refractory, triple negative
|
|
Study number:
|
BRE 126 SCRI
|
|
Protocol title:
|
Phase II Trial of Panitumumab, Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer
|
|
Status
|
Open
|
|
Study number:
|
BRE 156 Nippon Kayaku A6012211US
|
|
Protocol title:
|
A Phase II Study of NK012 in Locally Advanced Non-Resectable Metastatic Breast Cancer Patients with Triple Negative Phenotype
|
|
Status
|
Open
|
|
Study number:
|
BRE 185 Eli Lilly I1Y-MC-JFBE
|
|
Protocol title:
|
A Randomized Phase 2 Study of LY2523355 versus Ixabepilone in Patients with Metastatic Breast Cancer Who Have Received Prior Taxane Therapy
|
|
Status
|
Open
|